Korean expert consensus on the management of thrombotic thrombocytopenic purpura.

Although effective treatments, such as therapeutic plasma exchange, immunosuppressive therapy with rituximab, and caplacizumab, have significantly improved survival, important challenges remain.

These include limited diagnostic capacity, barriers to the early use of novel therapies, and long-term complications.

In Korea, additional difficulties persist due to the restricted availability of ADAMTS13 antibody testing, reimbursement limitations for rituximab, and the absence of caplacizumab in clinical practice.